Welcome to our dedicated page for CoreWeave SEC filings (Ticker: CRWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CoreWeave, Inc. (Nasdaq: CRWV) SEC filings page provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a publicly traded Software - Infrastructure company focused on AI cloud services, CoreWeave uses its filings to describe material agreements, financing arrangements, and significant corporate events.
In its Form 8-K filings, CoreWeave has reported material definitive agreements such as master services agreements and order forms with OpenAI, Meta Platforms, Inc., and NVIDIA Corporation, which govern access to cloud computing capacity and reserved capacity arrangements. The company has also disclosed credit agreements and delayed draw term loan facilities used to finance capital expenditures for GPU servers, infrastructure, and systems that support strategic customer contracts.
CoreWeave’s filings include detailed descriptions of its debt and capital structure, such as senior notes, revolving credit facilities, and convertible senior notes due 2031. These documents outline terms like interest rates, maturity dates, conversion features, capped call transactions, guarantees by subsidiaries, and financial covenants. Investors can review these filings to understand how CoreWeave funds its AI infrastructure and manages potential dilution.
Other 8-K filings cover topics such as the termination of a proposed merger agreement, changes in classification of equity related to preferred stock put rights, and the registration of Class A common stock on The Nasdaq Stock Market LLC under the symbol CRWV. Results of operations and financial condition for specific quarters are also furnished via 8-K exhibits.
On Stock Titan, AI-powered tools can help summarize lengthy CoreWeave filings, highlight key terms in documents like credit agreements and indentures, and surface information on topics such as material customer contracts, new financing facilities, and significant corporate events. Users can quickly locate references to items like convertible notes, capped call transactions, or major AI infrastructure commitments without reading every page.
CoreWeave, Inc. reported insider transactions involving trusts associated with Chief Development Officer Brannin McBee. On January 12, 2026, the Brannin J. McBee 2022 Irrevocable Trust converted 25,000 shares of Class B Common Stock into 25,000 shares of Class A Common Stock, and the Canis Major 2025 Family Trust LLC converted 1,000 Class B shares into 1,000 Class A shares, with each Class B share convertible 1-for-1 into Class A.
The McBee 2022 Irrevocable Trust then sold the 25,000 Class A shares in multiple trades, reducing its Class A holdings to zero, at weighted average prices disclosed in ranges such as $77.94 to $78.88 and up to $91.66 to $91.85, under a Rule 10b5-1 trading plan adopted on September 2, 2025. The Canis Major 2025 Family Trust LLC similarly sold its 1,000 Class A shares in multiple transactions at weighted average prices within ranges from $78.54 to $79.12 through $90.58 to $91.33, also ending with no Class A shares, while continuing to hold derivative positions in Class B Common Stock.
CoreWeave, Inc. Chief Development Officer McBee Brannin reported multiple equity transactions dated January 12, 2026. Brannin converted 102,835 shares of Class B Common Stock into the same number of Class A Common Stock and then sold portions of the Class A shares in a series of open-market transactions at weighted average prices that ranged from the high $70s to the low $90s per share under a pre-established Rule 10b5-1 trading plan. Following these sales, Brannin directly held 248,664 shares of Class A Common Stock and 8,705,815 shares of Class B Common Stock.
An affiliated entity, Canis Major 2024 Irrevocable Trust LLC, for which Brannin serves as manager, converted 3,000 shares of Class B Common Stock into Class A and sold those Class A shares in several trades at weighted average prices also in the upper $70s to low $90s. After these transactions, the trust held 600 shares of Class A Common Stock and 339,000 shares of Class B Common Stock.
A shareholder plans to sell 50,000 common shares under Rule 144, to be executed through Morgan Stanley Smith Barney LLC on or around January 14, 2026 on the NASDAQ. The filing shows an aggregate market value of $4,374,000 for this block, compared with 386,401,201 common shares outstanding. The shares were acquired as founder shares from the issuer on November 13, 2017 in a non-cash transaction.
Over the prior three months, the notice lists multiple Rule 10b5-1 sales of common stock for Michael Intrator and Omnadora Capital LLC, often in 50,000-share and 32,455-share blocks, with individual trade proceeds frequently in the millions of dollars. It also notes a 75,000-share sale by a non-affiliate donee. By signing, the selling person represents that they are not aware of undisclosed material adverse information about the issuer.
A Rule 144 notice reports a planned sale of 32,455 common shares of the issuer through Morgan Stanley Smith Barney LLC, with an aggregate market value of 2,839,163.40 and 386,401,201 shares outstanding, to be sold around 01/14/2026 on NASDAQ.
The shares to be sold are common stock originally acquired as founder shares from the issuer on 11/13/2017, in the same amount of 32,455, with payment dated 11/13/2017 and noted as N/A for the nature of payment.
The filing also lists prior three‑month sales of the issuer’s common stock for the account of the same overall selling group, including 10b5‑1 sales for MICHAEL INTRATOR of 61,386 shares on 01/06/2026 for gross proceeds of 4,674,746.47, and 10b5‑1 sales for OMNADORA CAPITAL LLC of 50,000 shares on several dates with multi‑million dollar proceeds.
This notice outlines a planned sale of 8,335 shares of common stock, to be executed through Morgan Stanley Smith Barney LLC on or about 01/12/2026 on the NASDAQ market. The filing reports an aggregate market value for these shares of $667,966.90, with 386,401,201 common shares outstanding. The shares to be sold were acquired on 02/25/2019 as founders shares from the issuer, with the full amount of 8,335 shares acquired on that date.
The document also lists prior sales of the issuer’s common stock during the past three months for the same overall selling group, largely under Rule 10b5-1 trading plans. Examples include a 01/05/2026 sale of 102,835 shares for $8,153,015.89 and a 12/01/2025 sale of 257,733 shares for $19,592,527.61 by a non-affiliate donee. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
A shareholder of CRWV has filed a Form 144 notice to sell 25,000 shares of common stock through Morgan Stanley Smith Barney on or about 01/12/2026, with trading on the NASDAQ. These shares were acquired on 02/25/2019 as founders shares. The filing reports that 386,401,201 common shares were outstanding. It also lists extensive recent Rule 10b5-1 sales of CRWV common stock over the prior three months by Brannin McBee, related trusts and entities, and a non-affiliate donee, including individual transactions such as 25,000-share sales by several trusts and a 257,733-share sale by a non-affiliate donee.
CRWV filed a Form 144 notice covering a planned sale of 1,000 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $80,140.00 and an approximate sale date of 01/12/2026 on NASDAQ. These shares were acquired as founder shares on 02/25/2019 from the issuer.
The filing also lists extensive sales of the issuer’s common stock during the prior three months by the same holder and related trusts under Rule 10b5-1 trading plans. Transactions include multiple December 2025 and January 2026 sales in blocks such as 102,835-share tranches for several million dollars each, and a separate sale by a non-affiliate donee of 257,733 shares on 12/01/2025 for $19,592,527.61.
A holder of common stock in the issuer submitted a Rule 144 notice covering a planned sale of 1,000 common shares through Morgan Stanley Smith Barney LLC on or about 01/12/2026 on the NASDAQ. The filing lists an aggregate market value of 80,140.00 for these shares and states that there were 386,401,201 common shares outstanding at the time.
The 1,000 shares to be sold were acquired on 02/25/2019 as founders shares directly from the issuer, with the table describing the nature of payment as “N/A.” The notice also details multiple Rule 10b5-1 sales of common stock during the prior three months by Brannin McBee, related trusts and entities, and a Non-Affiliate Donee, each entry specifying transaction dates in December 2025 and January 2026, share amounts sold, and gross proceeds.
CRWV has a notice to sell up to 3,000 shares of its common stock under Rule 144. The planned sale is to be executed through Morgan Stanley Smith Barney, with an aggregate market value of $240,420, and the company has 386,401,201 common shares outstanding. The shares to be sold are founder shares acquired on 02/25/2019 from the issuer.
The filing also lists numerous recent Rule 10b5-1 sales of CRWV common stock over the prior three months by Brannin McBee, related trusts and entities, and a non-affiliate donee, with individual transactions ranging from hundreds of shares to 257,733 shares in a single sale. These entries show significant ongoing selling activity under pre-arranged trading plans.
An insider of CRWV102,835 shares of common stock, with an aggregate market value of $8,241,196.90. The shares are expected to be sold through Morgan Stanley Smith Barney LLC on or around January 12, 2026 on the NASDAQ, and the issuer reports 386,401,201 common shares outstanding.
The securities to be sold were acquired as founder shares from the issuer on February 25, 2019, in a non-cash transaction labeled “N/A” for the nature of payment. The filing also lists extensive recent Rule 10b5-1 sales of CRWV common stock over the past three months by Brannin McBee, multiple related trusts and entities, and a non-affiliate donee, including a sale of 257,733 shares by a non-affiliate donee for $19,592,527.61 in gross proceeds.
FAQ
What is the current stock price of CoreWeave (CRWV)?
What is the market cap of CoreWeave (CRWV)?
